Objective To develop new classification criteria for systemic lupus erythematosus ( SLE )
jointly supported by the European League Against Rheumatism ( EULAR ) and the American …

The objective was to develop evidence-based recommendations for the management of
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …

ContextThere is substantial debate about whether the results of nonrandomized studies are
consistent with the results of randomized controlled trials on the same topic.ObjectivesTo …

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high
specificity for use in observational studies and trials, jointly supported by the American …

Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), …

Objective End‐stage renal disease (ESRD) is a major consequence of lupus nephritis, but
how this risk has changed over time is unknown. We conducted this systematic review to …

Objective Antiphospholipid antibodies (aPL), namely anticardiolipin antibodies (aCL) and
lupus anticoagulant (LAC), have been associated with an increased risk of thrombosis in …

Objective To evaluate the prevalence, clinical associations, and outcome of antiphospholipid
syndrome (APS) nephropathy in patients with systemic lupus erythematosus (SLE) and …

Antiphospholipid Syndrome (APS) is characterized by vascular thrombosis and/or pregnancy
morbidity occurring in patients with persistent antiphospholipid antibodies (aPL). The …

PURPOSE: We evaluated the prevalence and progression of Libman-Sacks endocarditis in
patients with systemic lupus erythematosus and any association between this valvulopathy …